Claire F. Verschraegen

Dr. Claire F. Verschraegen

Division of Medical Oncology, The Ohio State University, Columbus, Georgia, USA

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2010 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
SOS. J. O'Day
S. J. O'Day
MMMichele Maio
Michele Maio
VCVanna na Chiarion-Sileni
Vanna na Chiarion-Sileni
TGT. F. Gajewski
T. F. Gajewski
HPH. Pehamberger
H. Pehamberger
JWJ. D. Wolchok
J. D. Wolchok
Background: This phase II study evaluated the safety and activity of ipilimumab, a fully human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced melanoma. Patients and methods: Patients with previously treated, unresectable stage III/stage IV melanoma received 10 mg/kg ipilimumab every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months. The primary end point was best overall response rate (BORR) using modified World Health Organization (WHO) criteria. We also carried out an exploratory analysis of proposed immune-related response criteria (irRC). Results: BORR was 5.8% with a disease control rate (DCR) of 27% (N = 155). One- and 2-year survival rates (95% confidence interval) were 47.2% (39.5% to 55.1%) and 32.8% (25.4% to 40.5%), respectively, with a median overall survival of 10.2 months (7.6–16.3). Of 43 patients with disease progression by modified WHO criteria, 12 had disease control by irRC (8% of all treated patients), resulting in a total DCR of 35%. Adverse events (AEs) were largely immune related, occurring mainly in the skin and gastrointestinal tract, with 19% grade 3 and 3.2% grade 4. Immune-related AEs were manageable and generally reversible with corticosteroids. Conclusion: Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population.

1 May 2006 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
HSHarriet O. Smith
Harriet O. Smith
Marianne BerwickMarianne Berwick
Marianne Berwick
CVClaire Verschraegen
Claire Verschraegen
CWCharles Wiggins
Charles Wiggins
LLLetitia Lansing
Letitia Lansing
CQClifford R. Qualls
Clifford R. Qualls
OBJECTIVE: To evaluate 30-year, population-based trends in incidence and survival rates for malignant germ cell tumors originating within the female genital tract. METHODS: Surveillance, Epidemiology, and End Results data were used to identify malignant germ cell tumors (1973–2002). Overall and 5-year incidence rates, estimated annual percentage change, and survival rates were calculated and compared by age at diagnosis, race, stage, and histology. RESULTS: Of 1,262 cases, there were 414 (32.8%) dysgerminomas, 449 (35.6%) immature teratomas, 37 (2.9%) mature teratomas with malignant degeneration, and 362 (28.7%) mixed germ cell tumors. The 30-year, age-adjusted incidence rate per 100,000 women-years was 0.338, decreasing by 29.4% for dysgerminomas (P = .18) and by 31.5% for mixed germ cell tumors (P = .22). Other nonwhites had higher rates than whites and blacks, but dysgerminoma rates were higher in whites and other nonwhites than in blacks. Using the registries for expanded races, rates were higher for Asian/Pacific Islanders (P = .059) and Hispanics (P = .07). By age at diagnosis, 15–19 year olds had the highest rates and the only significant change in rates (37.5% increase, P = .008). The 5-year relative survival was 83.9%. Survival rates improved significantly over calendar time and varied by histologic subtype, race, stage of disease, and age at diagnosis. CONCLUSION: Over the past 30 years, germ cell tumor incidence rates have declined in women and differ from rising trends reported for testicular tumors. Survival rates have improved but were lower for older women and for nondysgerminoma subtypes. LEVEL OF EVIDENCE: II-3

20 January 2004 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
VVVincent Vinh-Hung
Vincent Vinh-Hung
CVClaire Verschraegen
Claire Verschraegen
Background: The objective of the study was to investigate whether radiotherapy or its omission after breast-conserving surgery has measurable consequences on local tumor growth and patient survival. Methods: We conducted a pooled analysis of published randomized clinical trials that compared radiotherapy versus no radiotherapy after breast-conserving surgery. The outcomes studied were ipsilateral breast tumor recurrence and patient death from any cause. The pooled relative risks (RRs) were estimated with a random-effects model. Heterogeneity was assessed using the Cochran Q test. Results: A search of the literature identified 15 trials with a pooled total of 9422 patients available for analysis. The relative risk of ipsilateral breast tumor recurrence after breast-conserving surgery, comparing patients treated with no radiotherapy or radiotherapy, was 3.00 (95% confidence interval [CI] = 2.65 to 3.40). Mortality data were available for 13 trials with a pooled total of 8206 patients. The relative risk of mortality was 1.086 (95% CI = 1.003 to 1.175), corresponding to an estimated 8.6% (95% CI = 0.3% to 17.5%) relative excess mortality if radiotherapy was omitted. Conclusion: Omission of radiotherapy is associated with a large increase in risk of ipsilateral breast tumor recurrence and with a small increase in the risk of patient mortality.

1 February 2012 in The Lancet
Verified
Journal Article
Closed access
PMPhilippe Morice
Philippe Morice
CUCatherine Uzan
Catherine Uzan
SGSebastien Gouy
Sebastien Gouy
CVClaire Verschraegen
Claire Verschraegen
CHChristine Haie-Meder
Christine Haie-Meder

9 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJason Luke
Jason Luke
SPSarina Anne Piha-Paul
Sarina Anne Piha-Paul
TMTheresa Medina
Theresa Medina
CVClaire Verschraegen
Claire Verschraegen
MVMary Varterasian
Mary Varterasian
FJFilip Janku
Filip Janku
Purpose: SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917 (EcN) engineered to produce cyclic dinucleotides under hypoxia, leading to STimulator of INterferon Genes (STING) activation in phagocytic antigen-presenting cells in tumors and activating complementary innate immune pathways. Patients and Methods: This first-in-human study (NCT04167137) enrolled participants with refractory advanced cancers to receive repeat intratumoral injections of SYNB1891 either alone or in combination with atezolizumab, with the primary objective of evaluating the safety and tolerability of both regimens. Results: Twenty-four participants received monotherapy across six cohorts, and 8 participants received combination therapy in two cohorts. Five cytokine release syndrome events occurred with monotherapy, including one that met the criteria for dose-limiting toxicity at the highest dose; no other SYNB1891-related serious adverse events occurred, and no SYNB1891-related infections were observed. SYNB1891 was not detected in the blood at 6 or 24 hours after the first intratumoral dose or in tumor tissue 7 days following the first dose. Treatment with SYNB1891 resulted in activation of the STING pathway and target engagement as assessed by upregulation of IFN-stimulated genes, chemokines/cytokines, and T-cell response genes in core biopsies obtained predose and 7 days following the third weekly dose. In addition, a dose-related increase in serum cytokines was observed, as well as stable disease in 4 participants refractory to prior PD-1/L1 antibodies. Conclusions: Repeat intratumoral injection of SYNB1891 as monotherapy and in combination with atezolizumab was safe and well tolerated, and evidence of STING pathway target engagement was observed.

1 September 2009 in Gynecologic Oncology
Verified
Journal Article
Closed access
HSHarriet O. Smith
Harriet O. Smith
Hugo Arias-PulidoHugo Arias-Pulido
Hugo Arias-Pulido
DKDennis Y. Kuo
Dennis Y. Kuo
THTamara Howard
Tamara Howard
CQClifford R. Qualls
Clifford R. Qualls
Eric R. ProssnitzEric R. Prossnitz
Eric R. Prossnitz